Top

Published in:

01-02-2014 | Healthcare Organization

Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group

Authors: Antonio Bertolotto, Marco Capobianco, Maria Pia Amato, Elisabetta Capello, Ruggero Capra, Diego Centonze, Maria Di Ioia, Antonio Gallo, Luigi Grimaldi, Luisa Imberti, Alessandra Lugaresi, Chiara Mancinelli, Maria Giovanna Marrosu, Lucia Moiola, Enrico Montanari, Silvia Romano, Luigina Musu, Damiano Paolicelli, Francesco Patti, Carlo Pozzilli, Silvia Rossi, Marco Salvetti, Gioachino Tedeschi, Maria Rosaria Tola, Maria Troiano, Mauro Zaffaroni, Simona Malucchi

Published in: Neurological Sciences | Issue 2/2014

Abstract

Interferon beta (IFNβ) was the first specific disease-modifying treatment licensed for relapsing-remitting multiple sclerosis, and is still one of the most commonly prescribed treatments. A strong body of evidence supports the effectiveness of IFNβ preparations in reducing the annual relapse rate, magnetic resonance (MRI) disease activity and disease progression. However, the development of binding/neutralizing antibodies (BAbs/NAbs) during treatment negatively affects clinical and MRI outcomes. Therefore, guidelines for the clinical use for the detection of NAbs in MS may result in better treatment of these patients. In October 2012, a panel of Italian neurologists from 17 MS clinics convened in Milan to review and discuss data on NAbs and their clinical relevance in the treatment of MS. In this paper, we report the panel’s recommendations for the use of IFNβ Nabs detection in the early identification of IFNβ non-responsiveness and the management of patients on IFNβ treatment in Italy, according to a model of therapeutically appropriate care.

Trojano M, Pellegrini F, Fuiani A, Paolicelli D, Zipoli V, Zimatore GB, Di Monte E, Portaccio E, Lepore V, Livrea P, Amato MP (2007) New natural history of interferon-beta-treated relapsing multiple sclerosis. Ann Neurol 61:300–306PubMedCrossRef

Bertolotto A, Malucchi S, Sala A, Orefice G, Carrieri PB, Capobianco M, Milano E, Melis F, Giordana MT (2002) Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory. J Neurol Neurosurg Psychiatry 73:148–153PubMedCrossRef

Sorensen PS, Deisenhammer F, Duda P, Hohlfeld R, Myhr KM, Palace J, Polman C, Pozzilli C, Ross C (2005) Guidelines on use of anti-IFN beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 12:817–827PubMedCrossRef

Polman CH, Bertolotto A, Deasenhammer F, Giovannoni G, Hartung HP, Hemmer B, Killestein J, McFarland HF, Oger J, Pachner AR, Petkau J, Reder AT, Reingold SC, Schellekeng H, Sorensen PS (2010) Recommendations for clinical use of data on neutralizing antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol 9(7):740–750PubMedCrossRef

Paolicelli D, D’Onghia M, Pellegrini F, Direnzo V, Iaffaldano P, Lavolpe V, Trojano M (2013) The impact of neutralizing antibodies on the risk of disease worsening in interferon b-treated relapsing multiple sclerosis: a 5 year post-marketing study. J Neurol 260(6):1562–1568PubMedCrossRef

Noyes K, Bajorska A, Chapel A, Schwid SR, Mehta LR, Weinstock-Guttman B, Holloway RG, Dick AW (2011) Cost-effectiveness of disease modifying therapy for multiple sclerosis. A population-based study. Neurology 77:355–363PubMedCrossRef

Brook RH (1994) Appropriateness of care: the new frontier. BMJ 308:218–219PubMedCrossRef

Fuchs VR (2011) The doctor’s dilemma—what is “appropriate” care ? NEJM 365(7):585–587PubMedCrossRef

Rio J, Comabella M, Montalban X (2009) Predicting responders to therapies for multiple sclerosis. Nat Rev Neurol 5(10):533–560CrossRef

10.

Sormani MP, De Stefano N (2013) Defining and scoring response to IFN β in multiple sclerosis. Nat Rev Neurol 9:504–512PubMedCrossRef

11.

Hardman JG, Limbird LE, Gilman AG (1996) The pharmacological basis of therapeutics. McGraw-Hill, New York

12.

Malucchi S, Gilli F, Caldano M, Sala A, Capobianco M, di Sapio A, Granieri L, Bertolotto A (2011) One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients. J Neurol 258:895–903PubMedCrossRef

13.

Bertolotto A, Gilli F (2008) Interferon-beta responders and non-responders. A biological approach. Neurol Sci 29:S216–S217PubMedCrossRef

14.

Sbardella E, Tomassini V, Gasperini C, Bellomi F, Cefano LA, Morra VB, Antonelli G, Pozzilli C (2009) Neutralizing antibodies explain the poor clinical response to interferon beta in a small proportion of patients with Multiple Sclerosis: retrospective study. BMC Neurol 9:54PubMedCentralPubMedCrossRef

15.

Rudick RA, Polman CH (2009) Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis. Lancet Neurol 8(6):545–559PubMedCrossRef

16.

Hesse D, Krakauer M, Lund H, Sondegaard HB, Langkilde A, Ryder LP, Sorensen PS, Sellebjerg F (2010) Breakthrough disease during interferon-beta therapy in MS: no signs of impaired biologic response. Neurol 4;74(18):1455–1462

17.

Steinberg SC, Faris RJ, Chang CF, Cham A, Tankersley MA (2010) Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study. Clin Drug Investig 30(2):89–100PubMedCrossRef

18.

Kobelt G, Berg J, Lindgren P, Battaglia M, Lucioni C, Uccelli A (2006) Costs and quality of life of multiple sclerosis in Italy. Eur J Health Econ 7(Suppl 2):S45–S54PubMedCrossRef

19.

Goldberg LD, Edwards NC, Fincher C, Doan QV, Al-Sabbagh A, Meletiche DM (2009) Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis. J Manag Care Pharm 15(7):543–555PubMed

20.

Hegen H, Millonig A, Bertolotto A, Comabella M, Giovanonni G, Guger M, Hoelzl M, Khalil M, Killestein J, Lindberg R, Malucchi S, Mehling M, Montalban X, Polman C, Rudzki D, Schautzer F, Sellebjerg F, Sørensen P, Deisenhammer F (2013) Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development. Mult Scler [Epub ahead of print]

21.

Sorensen PS, Koch-Henriksen N, Ross C, Clemmesen KM, Bendtsen K (2005) Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 65(1):33–39PubMedCrossRef

22.

Malucchi S, Sala A, Gilli F, Bottero R, Di Sapio A, Capobianco M, Bertolotto A (2004) Neutralizing antibodies reduce the efficacy of beta IFN during treatment of multiple sclerosis. Neurology 62:2031–2037PubMedCrossRef

23.

Creeke PI, Farrell RA (2013) Clinical testing for neutralizing antibodies to interferon-β in multiple sclerosis. Ther Adv Neurol Disord 6(1):3–17PubMedCentralPubMedCrossRef

24.

Sorensen PS, Ross C, Clemmensen KM, Bendtzen K, Frederiksen JL, Jensen K, Kristensen O, Petersen T, Rasmussen S, Ravnoborg M, Stenager E, Koch-Henriksen N, the Danish Multiple Sclerosis Study Group (2003) Clinical importance of neutralizing antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 362:1184–1191PubMedCrossRef

25.

Farrell RA, Marta M, Gaeguta AJ, Souslova V, Giovannoni G, Creeke PI (2012) Understanding drug resistance to biologic therapy. Development of resistance to biologic therapies with reference to IFN-β. Rheumatology 51(4):590–599PubMedCrossRef

26.

Bertolotto A, Malucchi S, Milano E, Castello A, Capobianco M, Mutani R (2000) Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations. Immunopharmacology 48:95–100PubMedCrossRef

27.

Barnard JG, Babcock K, Carpenter JF (2012) Characterization and quantitation of aggregates and particles in interferon-β products: Potential links between product quality attributes and immunogenicity. J Pharm Sci Dec 11. doi:10.1002/jps.23415. [Epub ahead of print]

28.

Hoffmann S, Cepok S, Grummel V, Lehmann-Horn K, Hackermüller J, Stadler PF, Hartung HP, Berthele A, Deisenhammer F, Wassmuth R, Hemmer B (2008) HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis. Am J Hum Genet 83(2):219–227PubMedCentralPubMedCrossRef

29.

Deisenhammer F, Schellekens H, Bertolotto A (2004) Measurement of neutralizing antibodies to interferon beta in patients with multiple sclerosis. J Neurol 251(Suppl 2):II31–II39PubMed

30.

Bertolotto A, Deisenhammer F, Gallo P, Soelberg Sorensen P (2004) Immunogenicity of interferon beta. Differences among products. J Neurol 251(suppl 2):II15–II24PubMed

31.

Comi G, De Stefano N, Freedman MS, Barkhof F, Polman CH, Kitdehaag BM, Casset-Semanaz F, Hennessy B, Moraga MS, Rocak S, Stubinski B, Kappos L (2012) Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomized controlled trial. Lancet Neurol 11(1):33–41PubMedCrossRef

32.

Cutter G (2003) Statistical issues in neutralizing antibodies. Neurology 61(Suppl 5):S38–S39PubMedCrossRef

33.

Hesse D, Sørensen PS (2007) Using measurements of neutralizing antibodies: the challenge of IFN-beta therapy. Eur J Neurol 14(8):850–859PubMedCrossRef

34.

The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group (1996) Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first 3 years. Neurology 47:889–894CrossRef

35.

The PRISMS (Prevention of Relapses and Disability by Interferon-β-1a Subcutaneously in Multiple Sclerosis) Study Group and the University of British Columbia MS/MRI Analysis Group (2001) PRISMS-4: long-term efficacy of interferon-β-1a in relapsing MS. Neurology 56:1628–1636CrossRef

36.

Kappos L, Clanet M, Sandberg W, Radue EW, Hartung HP, Hohlfeld R, Xu J, bennett D, Sandrock A, Goelz S and European Interferon beta-1a IM Dose-Comparison Study Investigators (2005) Neutralizing antibodies and efficacy of interferon β-1a: a 4 year controlled study. Neurology 65:40–47CrossRef

37.

Sormani MP, Bruzzi P (2013) MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials. Lancet Neurol 12(7):669–676PubMedCrossRef

38.

Francis GS, Rice GP, Alsop JC, PRISMS Study Group (2005) Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology 65:48–55PubMedCrossRef

39.

Rudick RA, Simonian NA, Alam JA, Campion M, Scaramucci JO, Jones W, Coats ME, Goodkin DE, Weinstock-Guttman B, Herndon RM, Mass MK, Richert JR, Salazar AM, Munschauer FF 3rd, Cookfair DL, Simon JH, Jacobs LD (1998) Incidence and significance of neutalizing antibodies to interferon beta 1a in multiple sclerosis. Neurology 50:1266–1272PubMedCrossRef

40.

Deisenhammer F, Reindel M, Harvey J, Gasse T, Dilitz E, Berger T (1999) Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology 52:1239–1243PubMedCrossRef

41.

Bertolotto A, Gilli F, Sala A, Audano L, Castello A, Magliola U, Melis F, Giordana MT (2001) Evaluation of bioavalability of three types of IFN beta in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification. J Immunol Methods 256:141–152PubMedCrossRef

42.

Pachner A, Narayan K, Price N, Hurd M, Dail D (2003) MxA gene expression analysis as an interferon-beta bioactivity measurement in patients with multiple sclerosis and the identification of antibody-mediated decreased bioactivity. Mol Diagn 7:17–25PubMed

43.

Wandinger KP, Lünemann JD, Wengert O, Bellmann-Strobl J, Aktas O, Weber A, Grundstrom E, Ehrlich S, Wernecke KD, Volk HD, Zipp F (2003) TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis. Lancet 361:2036–2043PubMedCrossRef

44.

Gilli F, Marnetto F, Caldano M, Sala A, Malucchi S, Capobianco M, Bertolotto A (2006) Biological markers of IFNβ therapy: comparison among interferon-stimulated-genes MxA, TRAIL, and XAF-1. Mult Scler 12:1–11CrossRef

45.

Pachner AR, Warth JD, Pace A, Goelz S, INSIGHT investigators (2009) Effect of neutralizing antibodies on biomarker responses to interferon beta. The INSIGHT study. Neurology 73:1493–1500PubMedCrossRef

46.

Sellebjerg F, Krakauer M, Hesse D, Ryder LP, Alsing I, Jensen PE, Koch-Henriksen N, Svejgaard A, Soelberg Sørensen P (2009) Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation. Eur J Neurol 16(12):1291–1298PubMedCrossRef

47.

Hesse D, Sellbjerg F, Sorensen PS (2009) Absence of MxA induction by interferon β in patients with MS reflects complete loss of bioactivity. Neurology 73:372–377PubMedCrossRef

48.

Zanotti C, Ghidini C, Lamorgese C, Caimi L, Capra R, Imberti L (2010) Transfer of myxovirus-protein-A mRNA assay for interferon-β bioactivity measurement in multiple sclerosis patients to routine laboratory practice. A 4-year experience. Clin Chem Lab Med 48(9):1235–1238PubMedCrossRef

49.

Malucchi S, Gilli F, Caldano M, Marnetto F, Valentino P, Granieri L, Sala A, Capobianco M, Bertolotto A (2008) Predictive markers for response to interferon therapy in patients with multiple sclerosis. Neurology 70(13 Pt 2):119–127

50.

Van der Voort, LF, Vennegoor A, Visser A, Knol DL, Kitdehaag BM, Barkhof F, Oudejans CB, Polman CH, Killestein J (2010) Spontaneous MxA mRNA level predicts relapses in patients with recently diagnosed MS. Neurol 5,75(14):1228–1233

51.

Bertolotto A, Gilli F, Sala A, Capobianco M, Malucchi S, Milano E, Melis F, Marnetto F, Linberg RL, Bottero R, Di Sapio A, Giordana MT (2003) Persistent neutralizing antibodies abolish the interferon β bioavailability in MS patients. Neurology 60:634–639PubMedCrossRef

52.

Capra R, Sottini A, Cordioli C, Serana F, Chiarini M, Caimi L, Padovani A, Bergamaschi R, Imberti L (2007) IFNbeta bioavailability in multiple sclerosis patients: MxA versus antibody-detecting assays. J Neuroimmunol 189(1–2):102–110PubMedCrossRef

53.

Fitzgerald S (2009) Antibodies block effect of interferon on MS. Neurology Today 9(15):14CrossRef

54.

Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group (2001) Randomized controlled trial of interferon-beta-1a in secondary progressive MS: Clinical results. Neurology 56:1496–1504CrossRef

55.

Panitch H, Goodin DS, Francis G, Chang P, Coyle PK, O’Connor P, Monaghan E, Li D, Weinshenker B for the EVIDENCE (Evidence of Interferon Dose-Response: European North American Comparative Efficacy) Study Group and the University of British Columbia MS/MRI Research Group (2002) Randomized, comparative study of interferonβ-1a treatment regimens in MS. The EVIDENCE Trial. Neurol 59:1496–1506

56.

Durelli L, Verdun E, Barbero P, Bergui M, Versino E, Chezzi A, Montanari E, Zaffaroni M, the Independent COMparison of Interferon (INCOMIN) Trial Study Group (2002) Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 359:1453–1460PubMedCrossRef

57.

Polman C, Kappos L, White R, Dahlke F, beckmann K, Pozzilli C, Thompson A, Petkau J, Miller D (2003) Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b. Neurology 60:37–43PubMedCrossRef

58.

The North American Study Group on Interferon beta-1b in Secondary Progressive MS (2004) Interferon beta-1b in secondary progressive MS. Results from a 3-year controlled study. Neurology 3:1788–1795CrossRef

59.

Hartung H-P, Freedman MS, Polman CH, Edan G, Kappos L, Miller DH, Montalban X, Barkhof F, Petkau J, White R, Sahajpal V, Knappertz V, Beckmann K, Lanius V, Sandbrink R, Pohl C, For the BENEFIT Study Group (2011) Interferon β-1b—neutralizing antibodies 5 years after clinically isolated syndrome. Neurology 77:835–843PubMedCrossRef

60.

Frank JA, Richert N, Bash C, Stone L, Calabresi PA, Lewis B, Stone R, Howard T, McFarland HF (2004) InterferonB-1b slows progression of atrophy in RRMS. Three-year follow-up in NAb and Nab patients. Neurology 62:719–725PubMedCrossRef

61.

Perini P, Calabrese M, Biasi G, Gallo P (2004) The clinical impact of interferon beta antibodies in relapsing-remitting MS. J Neurol 251:305–309PubMedCrossRef

62.

Tomassini V, Paolillo A, Russo P, Giugni E, Prosperini L, Gasperini C, Antonelli G, Bastianello S, Pozzilli C (2006) Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis. J Neurol 253:287–293PubMedCrossRef

63.

Boz C, Oger J, Gibbs E, Grossberg SE (2007) Reduced effectiveness of long-term interferon-treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study. Mult Scler 13:1127–1137PubMedCrossRef

64.

Durelli L, Barbero P, Berqui M, Versino E, Bassano MA, Verdun E, Rivoiro C, Ferrero C, Picco E, Ripellino P, Giuliani G, Montanari E, Clerico M (2008) MRI activity and neutralising antibody as predictors of response to interferon b treatment in multiple sclerosis. J Neurol Neurosurg Psychiatry 79:646–651PubMedCrossRef

65.

Li DK, Zhao GJ, Paty DW, University of British Columbia MS/MRI Analysis Research Group, The SPRECTRIMS Study Group (2001) Randomized controlled trial of interferon-beta 1a in secondary progressive MS: MRI results. Neurology 56(11):1505–1513PubMedCrossRef

66.

Sato DK, Nakashima I, Fukazawa T, Shimizu Y, Tomizawa Y, Yokoyama K, Misu T, Creeke PI, Farrell R, Giovannoni G, Itoyama Y, Fujihara K, Aoki M (2012) Neutralizing antibodies are associated with a reduction of Interferon-b efficacy during the treatment of Japanese Multiple sclerosis patients. Tohoky J Exp Med 228:85–92CrossRef

Title: Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group
Authors: Antonio Bertolotto
Marco Capobianco
Maria Pia Amato
Elisabetta Capello
Ruggero Capra
Diego Centonze
Maria Di Ioia
Antonio Gallo
Luigi Grimaldi
Luisa Imberti
Alessandra Lugaresi
Chiara Mancinelli
Maria Giovanna Marrosu
Lucia Moiola
Enrico Montanari
Silvia Romano
Luigina Musu
Damiano Paolicelli
Francesco Patti
Carlo Pozzilli
Silvia Rossi
Marco Salvetti
Gioachino Tedeschi
Maria Rosaria Tola
Maria Troiano
Mauro Zaffaroni
Simona Malucchi
Publication date: 01-02-2014
Publisher: Springer Milan
Published in: Neurological Sciences / Issue 2/2014
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-013-1616-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2014

Factors of Hamilton Depression Rating Scale (17 items) at 2 weeks correlated with poor outcome at 1 year in patients with ischemic stroke

Healthcare quality in a fragmented society: the Lebanese model

Influence of human myasthenia gravis thymus on the differentiation of human cord blood stem cells in SCID mice

Hippocampal expression of aryl hydrocarbon receptor nuclear translocator 2 and neuronal PAS domain protein 4 in a rat model of depression

Quantitative evaluation of hyperbaric oxygen efficacy in experimental traumatic brain injury: an MRI study

Neurophysiological and immunohistochemical studies of IgG anti-GM1 monoclonal antibody on neuromuscular transmission: effects in rat neuromuscular junctions